Carey Hwang

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

Cynthia L. Gay, Ronald J. Bosch, Justin Ritz et al. · The Journal of Infectious Diseases · 2017 · 219 citations · Full text

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

Chloe Orkin, Kathleen Squires, Jean‐Michel Molina et al. · Clinical Infectious Diseases · 2018 · 159 citations · Full text

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2018 · 140 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +7

Assessment of Pharmacokinetic Interactions of the HCV Ns5A Replication Complex Inhibitor Daclatasvir with Antiretroviral Agents: Ritonavir-Boosted Atazanavir, Efavirenz and Tenofovir

Marc Bifano, Carey Hwang, B. Oosterhuis et al. · Antiviral Therapy · 2013 · 92 citations

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

Margaret Johnson, Princy Kumar, Jean‐Michel Molina et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 92 citations · Full text